Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

Autor: Jonathan S. Zager, Christopher A. Puleo, Anne M. Wallace, Julian A. Kim, Vernon K. Sondak, Schlomo Schneebaum, Dennis King, Lori Christman, Steve R. Martinez, Mark B. Faries, Jane L. Messina, Stanley P. L. Leong, Bruce J. Averbook
Rok vydání: 2012
Předmět:
Zdroj: Annals of Surgical Oncology
ISSN: 1534-4681
1068-9265
Popis: Background [99mTc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [99mTc]tilmanocept to vital blue dye. Methods Patients received [99mTc]tilmanocept and blue dye. SLNs identified intraoperatively as radioactive and/or blue were excised and histologically examined. The primary end point, concordance, was the proportion of blue nodes detected by [99mTc]tilmanocept; 90 % concordance was the prespecified minimum concordance level. Reverse concordance, the proportion of radioactive nodes detected by blue dye, was also calculated. The prospective statistical plan combined the data from both trials. Results Fifteen centers contributed 154 melanoma patients who were injected with both agents and were intraoperatively evaluated. Intraoperatively, 232 of 235 blue nodes were detected by [99mTc]tilmanocept, for 98.7 % concordance (p
Databáze: OpenAIRE